Should I buy Bliss GVS Pharma stock in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of Bliss GVS Pharma for over three years. Every month, over a million users in India trust us to decipher market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Bliss GVS Pharma.

What is Bliss GVS Pharma?

Bliss GVS Pharma Stock Price

The price of Bliss GVS Pharma stock is rising this week. The current share price is ₹156.25, with a small 24-hour change of -0.04% and a strong weekly gain of 5.00%. Market capitalization stands at ₹16.42 billion, and average three-month trading volume is 768,589 shares. The Price/Earnings Ratio is 19.56, the dividend yield is 0.32%, and the stock beta is 1.21, signaling higher volatility than the market. Investors should be aware of recent swings, as Bliss GVS Pharma offers significant movement opportunities in the pharmaceutical sector.

Our full analysis of the Bliss GVS Pharma stock

After an in-depth evaluation of Bliss GVS Pharma’s latest quarterly figures and its share price trajectory over the past three years, our expert analysis synthesizes financial metrics, technical signals, peer benchmarking, and market data through advanced algorithms. By combining these insights, we reveal a compelling case for renewed attention to this Indian pharmaceutical leader. So, why might Bliss GVS Pharma stock once again become a strategic entry point into the fast-evolving healthcare and pharmaceuticals sector in 2025?

Recent performance and market context

Bliss GVS Pharma has recently delivered a strong week in the Indian markets, with its share price gaining 5% to reach ₹156.25 on the NSE as of July 4, 2025. This comes after a longer-term rally, as the stock has soared 51.21% over the past year, far outpacing sector benchmarks and catching the attention of institutional investors. While the last six months reflected a -12.44% correction, the resilience of the weekly trend and price stability near fresh resistance zones signal robust underlying demand. Significantly, the company’s board approved a new round of sweat equity issuance in May 2025 and recommended a final dividend of ₹0.50 per share, reinforcing management’s proactive approach to value creation. Promoters increasing their stake to 35.29% further highlight internal confidence in the company’s growth trajectory. These corporate actions, combined with India’s ongoing healthcare sector expansion, have catalyzed new interest in the stock. The macro environment remains exceptionally supportive: rapid urbanization, rising healthcare awareness, and regulatory momentum are fuelling sustained demand for pharmaceutical innovation, with domestic and export opportunities at the forefront.

Technical analysis

From a technical perspective, Bliss GVS Pharma shows promising bullish momentum across most key indicators. The 14-day RSI stands at 66.49, reflective of a slightly overbought yet still healthy bullish environment, rather than a short-term overheating. The MACD (12,26,9) reading at 6.41 is convincingly above its signal line, providing an ongoing buy signal as new money enters the counter. All major moving averages are supportive: the stock is currently trading above its 20-day (₹148.01), 50-day (₹133.58), 100-day (₹129.92), and 200-day (₹137.46) moving averages. This broad alignment across multiple timeframes reinforces the strength of the recent breakout.

Critical technical supports at ₹153.96 (S1) and ₹151.61 (S2) have held firm even through minor corrections, offering a solid buffer for new entries. On the upside, resistance at ₹159.70 (R1) and ₹163.09 (R2) presents clear technical milestones; a close above these levels could fuel a further bullish expansion. From a trend standpoint, the stock trades decisively above all its major averages, confirming sustained positive sentiment. With a 1-year beta of 1.21, volatility is slightly elevated relative to the market—opening the door to dynamic short- and medium-term trading opportunities for those who manage risk wisely.

Fundamental analysis

Fundamentally, Bliss GVS Pharma stands out as an agile mid-cap player with a proven record of profitability and innovation. The latest quarterly revenue (Q4 FY2025) was ₹156 crores, while annual revenues and net profit reflect resilience and adaptability. Despite a short-term EBITDA decline (-26.4% quarter-on-quarter), the company remains profitable, with net income consistently positive and diluted EPS at a solid ₹8.0 for the quarter. Over the last year, annual sales have grown by 3.27% and the company closed FY2025 with improved operating leverage.

Its valuation remains attractive relative to peers: the P/E ratio stands at 19.56, indicating a fair pricing point as compared with the broader Indian pharma segment—often supporting even higher multiples for established export leaders. The dividend yield, though modest at 0.32%, acts as a positive signal of management’s balanced capital allocation policy.

Structural strengths include:

• Global leadership in niche markets such as suppositories and pessaries, with a massive portfolio exceeding 250 branded formulations.
• World-class manufacturing facilities and a sterling reputation for regulatory compliance, supporting competitive advantages in both domestic and over 60 international markets.
• Agility to navigate regulatory, pricing, and raw material headwinds, as proven by a solid track record of innovation and cost management.

In short, the fundamentals justify renewed investor interest and underpin the long-term investment case.

Volume and liquidity

Liquidity is reliably strong for Bliss GVS Pharma shares, with an average daily trading volume of 768,589 shares (30-day average, NSE). This ensures ease of entry and exit for both institutional and retail participants, facilitating dynamic price discovery and reducing the risk of illiquidity-driven volatility. The company’s float structure, with 35.29% held by promoters and the rest widely distributed, is conducive to a lively yet stable market for the stock.

Such sustained volume—especially when accompanied by bullish price action—signifies robust market confidence and often precedes medium-term re-ratings.

Catalysts and positive outlook

Bliss GVS Pharma’s forward prospects are underpinned by a powerful mixture of near-term and structural catalysts. Of particular note:

• The company’s status as a world leader in manufacturing specialty pharmaceuticals positions it as a primary beneficiary of the ongoing global generics and specialty drug boom.
• Strategic investments in expanding product lines and export capacity, most notably in Africa, Southeast Asia, and the Middle East, are set to deliver incremental revenue streams and hedged growth.
• Regulatory approvals and product launches expected in FY2026 are potential game-changers, offering strong triggers for earnings surprises.
• Increased promoter shareholding and board approvals for sweat equity suggest alignment of management incentives with shareholder value creation—a crucial factor for sustainable outperformance.
• The broader sector’s macro tailwinds—India’s focus on pharmaceutical exports, Make-in-India policy initiatives, and incentives for innovation—are likely to keep sectoral valuations strong, benefiting leading names such as Bliss GVS Pharma.

Additionally, operational enhancements, process automation, and green-field expansions in domestic and international facilities point toward rising efficiency and margin retention even as cost-side pressures ebb.

Investment strategies

For investors considering entry into Bliss GVS Pharma, today’s environment presents several compelling strategic windows:

• Short-term traders can seek opportunities around established support levels (₹153.96 and ₹151.61), with clear upside targets at resistance points (₹159.70 and ₹163.09). The technical structure suggests range trading or breakout strategies may be especially effective, backed by rising volume and momentum.
• Medium-term investors should focus on upcoming earnings releases, regulatory approvals, and export contract wins as catalysts for potential rerating. Building a position ahead of these key events could prove beneficial, with stop-losses set just below main supports.
• Long-term portfolio builders will appreciate Bliss GVS Pharma’s leadership position in a well-defended global niche, its disciplined capital management, and its proven ability to deliver sustainable earnings despite sector cyclicality. Accumulating on minor dips, or scaling in with a focus on major technical supports, can optimize long-term return potential while managing volatility.

It is advisable to monitor broader pharma sector flows, competitive actions, and policy developments to maximize entry timing and capture favorable momentum. The current technical and fundamental overlap points to an optimal period for phased accumulation or tactical trading.

Is it the right time to buy Bliss GVS Pharma?

Bringing together robust fundamentals, technical confidence, and a raft of visible catalysts, Bliss GVS Pharma seems to represent an excellent opportunity at its current levels. The combination of global leadership, management alignment, broadening product scope, and sector tailwinds provides compelling potential for sustained outperformance. While short-term volatility (beta 1.21) calls for risk discipline, the trading volume and liquidity profile bolster the case for considering meaningful exposure within a diversified portfolio.

Looking ahead, as India’s healthcare and pharmaceutical sectors continue to expand and innovate, Bliss GVS Pharma’s specialized strengths, expanding global reach, and consistent profitability mean the stock may well be entering a fresh bullish phase. For investors seeking growth, innovation, and sector leadership, this is a high-conviction opportunity worthy of close attention as 2025 unfolds.

How to buy Bliss GVS Pharma stock in India?

Buying Bliss GVS Pharma stock online is easy and secure with any regulated broker operating in India. Investors typically select between two main approaches: spot buying—which means directly owning the company’s shares—or using CFDs (Contracts for Difference) to trade on price movements without owning the underlying asset. Each method has its own costs and advantages, and you’ll find a detailed broker comparison further down the page to help you make the right choice.

Spot buying

When you purchase Bliss GVS Pharma shares for cash, you become a direct shareholder, benefiting from any dividends and potential capital appreciation. The process involves paying the full value of the shares up front, plus a typical flat commission charged by Indian brokers (for example, around ₹100–₹200 or about $5 per order).

Gain scenario for Bliss GVS Pharma stock

If the Bliss GVS Pharma share price is $1.87 (approximately ₹156.25), you can buy around 533 shares with a $1,000 stake, including a brokerage fee of around $5.

Gain scenario:

If the share price rises by 10%, your shares are now worth $1,100.

Result: +$100 gross gain, i.e. +10% on your investment.

Trading via CFD

With CFDs, you don’t own Bliss GVS Pharma shares, but you can profit from both rising and falling prices. CFDs also allow leverage, so a small deposit can control a much larger market position. Fees include the spread (the small difference between buy and sell prices) and, for leveraged positions held overnight, a daily financing charge.

CFD Trading: Gain Scenario

You open a CFD position on Bliss GVS Pharma shares, with 5x leverage. This gives you a market exposure of $5,000.

✔️ Gain scenario: If the stock rises by 8%, your position gains 8% × 5 = 40%.

Result: +$400 gain, on a bet of $1,000 (excluding fees).

Final advice

Always compare the commissions, spreads, and conditions offered by different brokers before investing. Whether you choose to buy Bliss GVS Pharma shares outright or trade via CFDs depends on your investment objectives, risk appetite, and desired time frame. Remember—a broker comparison is available further down the page to help you get started as an informed investor.

Our 7 tips for buying Bliss GVS Pharma stock

The latest news about Bliss GVS Pharma

Bliss GVS Pharma stock delivers a strong weekly gain, outperforming sector benchmarks. Over the past seven days, Bliss GVS Pharma stock has risen by 5%, significantly outpacing both the Nifty Pharma index and the broader market. This momentum is supported by robust investor interest and healthy trading volumes averaging 768,589 shares per session.

Technical indicators signal continued bullish sentiment for Bliss GVS Pharma on the NSE. The stock is now trading above its 20, 50, 100, and 200-day moving averages, demonstrating technical strength. The current MACD and RSI values suggest buy signals, reinforcing the positive outlook echoed by market participants in India.

Promoters increase their stake in Bliss GVS Pharma, signaling long-term confidence. In the most recent quarter, promoter shareholding ticked up from 35.10% to 35.29%. This incremental rise is seen as a constructive vote of confidence, aligning controlling interests with minority investors and underlining management’s positive mid- to long-term outlook.

Bliss GVS Pharma Board approves sweat equity share issue to support talent retention and growth. A resolution passed in May 2025 allows for sweat equity shares, reflecting a commitment to incentivize key talent and drive future innovation. Such initiatives can strengthen the company’s position as a leader in branded pharmaceutical formulations for the domestic market.

Final dividend of ₹0.50 per share recommended, reinforcing shareholder value creation. For the financial year ending March 2025, the Board has recommended a final dividend, highlighting profitability and a continued policy of shareholder reward. This also demonstrates the company’s consistent cash generation in the face of industry headwinds.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.